Intezyne

Combination of Checkpoint Inhibitors and Intezyne's Novel Cancer Resistance Pathway Inhibitor IT-139 Shows Enhanced Immune Efficacy   See more here

Intezyne Partners with Exosome Diagnostics on IT-139 Companion Diagnostic   See more here

Intezyne Taps Veteran Banker E. Russell McAllister  as President and CEO   See more here

Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development  See more here

Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer  See more here

Intezyne Technologies Initiates First-In-Human Trials for Topoisomerase-1 Inhibitor IT-141; GRP78 Inhibitor IT-139 to be Featured in AACR Symposium  See more here

Intezyne Technologies Expands Executive Leadership Team with Two Key Appointments Read more here

Intezyne Technologies Expands Its Oncology Pipeline Through Strategic Acquisition of Niiki Pharma Read more here